Quantum-Si (NASDAQ:QSI) Stock Rating Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Quantum-Si from “Sell” to “Hold,” bringing the overall analyst consensus to “Hold.” The average price target is $2.50, with ratings split between two Buys, one Hold, and one Sell.
• Quantum-Si shares rose 25.4% to open at $1.53, compared with a 12-month range of $0.69 to $3.10. HC Wainwright set a $4.00 price target.
• The company reported a quarterly loss of $0.11 per share, in line with estimates, and revenue of $340,000. Quantum-Si develops proteomics tools, including its Platinum protein-sequencing platform, but continues to post significant net losses.

Quantum-Si (NASDAQ:QSI - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Sunday, Wall Street Zen reports.

A number of other brokerages have also commented on QSI. HC Wainwright set a $4.00 price target on shares of Quantum-Si in a report on Friday. Weiss Ratings raised Quantum-Si from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 24th. Finally, Alliance Global Partners reaffirmed a "buy" rating on shares of Quantum-Si in a research note on Friday, August 14th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Quantum-Si presently has a consensus rating of "Hold" and an average target price of $2.50.

Quantum-Si Trading Up 25.4%

Shares of QSI stock opened at $1.53 on Friday. Quantum-Si has a 12 month low of $0.69 and a 12 month high of $3.10. The stock has a market capitalization of $334.89 million, a P/E ratio of -3.33 and a beta of 3.21. The firm's 50 day moving average is $0.86 and its 200 day moving average is $0.90.

Quantum-Si (NASDAQ:QSI - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.11) EPS for the quarter, meeting analysts' consensus estimates of ($0.11). The company had revenue of $0.34 million during the quarter, compared to analyst estimates of $0.30 million. Quantum-Si had a negative net margin of 6,138.26% and a negative return on equity of 47.12%. On average, equities analysts predict that Quantum-Si will post -0.47 EPS for the current year.

Institutional Trading of Quantum-Si

Several hedge funds have recently added to or reduced their stakes in QSI. IPG Investment Advisors LLC bought a new position in shares of Quantum-Si during the second quarter valued at about $27,000. WINTON GROUP Ltd purchased a new stake in Quantum-Si during the 2nd quarter valued at about $67,000. Corient Private Wealth LP bought a new position in Quantum-Si during the 2nd quarter worth approximately $34,000. Green Alpha Advisors LLC purchased a new position in Quantum-Si in the 2nd quarter worth approximately $41,000. Finally, Renaissance Technologies LLC bought a new stake in Quantum-Si in the first quarter valued at approximately $91,000. 39.90% of the stock is owned by institutional investors.

About Quantum-Si

Quantum-Si Incorporated NASDAQ: QSI is a life sciences technology company focused on advancing proteomics, the study of proteins and their functions. The company develops tools intended to make protein analysis more accessible, scalable and cost-effective for researchers, pharmaceutical companies, biotechnology firms and academic institutions.

Its primary offering is the Platinum platform, which combines a benchtop protein sequencing instrument with single-use consumables and software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.